Literature DB >> 20832138

Regulation of immunological disorders by invariant Vα19-Jα33 TCR-bearing cells.

Michio Shimamura1, Yi-Ying Huang, Hiroshi Goji, Shin Endo, Rika Migishima, Minesuke Yokoyama.   

Abstract

We have previously shown that over-expression of the invariant Vα19-Jα33 TCR α transgene (Tg) using a natural TCR α promoter in mice induces the development of NK1.1(+) T cells (Vα19 NKT cells) in lymphoid organs, including the liver and intestine. These cells produce different spectra of immunoregulatory cytokines such as IL-4, IL-10, IL-17, and IFN-γ depending on the duration and intensity of the invariant TCR stimulation. In this study, we examined the effects of over-expression of invariant Vα19-Jα33 TCR-bearing cells on disease progress in the models of immunological disorders. The introduction of invariant Vα19 TCR Tg into non-obese diabetic mice delayed the onset of the disease. In addition, delayed-type hypersensitivity (DTH) to sheep erythrocytes was suppressed in the Vα19 Tg mice. DTH was also suppressed in the wild type mice previously transferred with Vα19 Tg(+) but not non-Tg cells. Thus, invariant Vα19 TCR-bearing cells are suggested to participate in the homeostasis of immunity to suppress disease progression resulting from Th1-immunity excess.
Copyright © 2010 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20832138     DOI: 10.1016/j.imbio.2010.08.003

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  9 in total

1.  Polyclonal mucosa-associated invariant T cells have unique innate functions in bacterial infection.

Authors:  Wei-Jen Chua; Steven M Truscott; Christopher S Eickhoff; Azra Blazevic; Daniel F Hoft; Ted H Hansen
Journal:  Infect Immun       Date:  2012-07-09       Impact factor: 3.441

2.  Treatment with incomplete Freund's adjuvant and Listeria monocytogenes delays diabetes via an interleukin-17-secretion-independent pathway.

Authors:  Hai-Ping Wang; Zhi-Gao He
Journal:  Exp Ther Med       Date:  2015-03-03       Impact factor: 2.447

Review 3.  Mucosal-associated invariant T cells from induced pluripotent stem cells: A novel approach for modeling human diseases.

Authors:  Chie Sugimoto; Hiroyoshi Fujita; Hiroshi Wakao
Journal:  World J Stem Cells       Date:  2016-04-26       Impact factor: 5.326

Review 4.  Therapeutic manipulation of natural killer (NK) T cells in autoimmunity: are we close to reality?

Authors:  Y Simoni; J Diana; L Ghazarian; L Beaudoin; A Lehuen
Journal:  Clin Exp Immunol       Date:  2013-01       Impact factor: 4.330

Review 5.  Mucosal-associated invariant T cells and disease.

Authors:  Amine Toubal; Isabelle Nel; Sophie Lotersztajn; Agnès Lehuen
Journal:  Nat Rev Immunol       Date:  2019-10       Impact factor: 53.106

6.  Modulation of immunoglobulin production by invariant Vα19-Jα33 TCR-bearing cells.

Authors:  Michio Shimamura; Yi-Ying Huang; Hiroshi Hidaka
Journal:  PLoS One       Date:  2011-06-16       Impact factor: 3.240

Review 7.  iNKT and MAIT Cell Alterations in Diabetes.

Authors:  Isabelle Magalhaes; Badr Kiaf; Agnès Lehuen
Journal:  Front Immunol       Date:  2015-07-02       Impact factor: 7.561

8.  Reprogramming and redifferentiation of mucosal-associated invariant T cells reveal tumor inhibitory activity.

Authors:  Chie Sugimoto; Yukie Murakami; Eisuke Ishii; Hiroyoshi Fujita; Hiroshi Wakao
Journal:  Elife       Date:  2022-04-05       Impact factor: 8.713

Review 9.  MAIT cells: new guardians of the liver.

Authors:  Ayako Kurioka; Lucy J Walker; Paul Klenerman; Christian B Willberg
Journal:  Clin Transl Immunology       Date:  2016-08-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.